The patient at the centre of activities... on the road to a cure

The Myeloma Canada Chair: improving care, innovating through research, disseminating knowledge.


Meet the team

A medical team dedicated to patients with multiple myeloma at Hôpital Maisonneuve-Rosemont.

  • Dr. Richard LeBlanc

    Dr. Richard LeBlanc

    A hematologist and medical oncologist, he holds the Université de Montréal Myeloma Canada Chair on multiple myeloma at…

  • Dr Richard LeBlanc

    Dr Richard LeBlanc

    Hématologue et oncologue médical, il est titulaire de la Chaire Myélome Canada sur le myélome multiple de l’Université…

  • Dr Jean Roy

    Dr Jean Roy

    Hématologue et chef du service d’hématologie et d’oncologie de l’HMR, il est spécialiste de la transplantation de cellules…

View all team members


Patients with multiple myeloma, their loved ones, staff and partners of the Chair reflect fondly on their experience in various aspects of care and patient management.

  • In medicine, and in oncology in particular, there is a kind of explosion of information and knowledge. This is certainly beneficial, but this mountain of information often needs to be classified and interpreted by experts on the matter. To speak more particularly about multiple myeloma, it is clear that having access to clinical data that is relevant and classified in the form of a website greatly improves the management of patients with this pathology and, in a word, the quality of medical care.

    Dr Hossein Jamali ,

  • En médecine et en particulier en oncologie on assiste à une sorte d'explosion d'information et de savoir. Ceci est certainement bénéfique mais cette montagne d'information a souvent besoin d'être classifiée et interprétée par des experts en la matière. Pour parler plus particulièrement de myélome multiple il est évident que d'avoir accès à des données cliniques pertinentes et classifiées sous forme d'un site internet améliore grandement la prise en charge des patients atteints de cette pathologie et en un mot, la qualité des soins médicaux.

    Dr Hossein Jamali ,

  • April 2011: Time stops. I learn that I have multiple myeloma. The future has changed drastically, and a period of questioning about my life and what to do is set into motion. My first visits in oncology are a shock: What is going on? January 2012: My proteins continue to rise. The decision is made to begin intravenous chemotherapy. My treatment begins with Velcade, which has just been accepted as a first-line drug in the treatment of myeloma. So I am hopeful as I undertake my journey towards my life goal: remission. Subsequently, through research, another option is offered to me, the administration of Revlimid pills. This drug, also relatively recent, allows me to achieve results that make me eligible for an autologous bone marrow transplant at Hôpital Maisonneuve-Rosemont. Thanks to this team, I get this new breath of life. May 2013: I am in remission. That said, without the active participation of researchers, these precious scientists, we would be at the mercy of this terrible disease. My story is one of hope that allows us to believe that we will overcome myeloma. An early diagnosis, increasingly more specific treatments and the support of a devoted multidisciplinary team at Hôpital Maisonneuve-Rosemont allow me to view the future with hope and determination. I encourage everyone to give what they can to improve the living conditions of people affected by the disease. These gifts will help to make sure that our researchers, including Dr. Richard LeBlanc, can one day discover a way to eliminate the disease. To give is to offer life to people who would have been doomed only a few years ago. Encouraging research is the solution for a warmer future.

    Nicole Chartier, patient ,

  • Avril 2011, le temps s’arrête. J’apprends que j’ai un myélome multiple. L’avenir vient de changer du tout au tout et une période de questionnements sur ma vie et ce qu’il y a à faire s’enclenche. Mes premières consultations en oncologie s’avèrent un choc, que se passe-t-il? Janvier 2012, mes protéines continuent de monter. La décision de débuter la chimiothérapie intraveineuse est prise. Débutent mes traitements au Velcade qui vient tout juste d’être accepté comme médicament de première intention dans le traitement du myélome. C’est donc plein d’espoir que j’entreprends ma marche vers mon objectif de vie, la rémission. Par la suite, grâce à la recherche, une autre option s’offre à moi, l’administration de Revlimid en pilules. Ce médicament, lui aussi relativement récent, me permet d’atteindre des résultats qui me rendent éligible à la greffe autologue de moelle osseuse à l’Hôpital Maisonneuve-Rosemont. Grâce à cette équipe, je reçois ce nouveau souffle de vie. Mai 2013, je suis en rémission. Ceci dit, sans la participation active des chercheurs, de ces scientifiques si précieux, nous serions à la merci de cette terrible maladie. Mon histoire en est une d’espoir qui nous permet de croire que nous vaincrons le myélome. Un diagnostic précoce, des traitements de plus en plus spécifiques et le support de l’équipe multidisciplinaire dévouée de l’Hôpital Maisonneuve-Rosemont me permettent d’envisager l’avenir avec espoir et détermination. J’encourage chacun à donner ce qu’il peut afin d’améliorer la condition de vie des gens affectés par la maladie. Ces dons feront en sorte que nos chercheurs, dont le Dr Richard Leblanc, puissent arriver à découvrir un moyen d’éliminer la maladie. Donner c’est offrir la vie à des gens qui étaient condamnés il y a quelques années. Encourageons la recherche c’est la solution pour un avenir plus clément.

    Nicole Chartier, patiente ,

  • Following my assessment, my appointment, which had been scheduled for July, was moved up. So it was with great apprehension that on June 17, 2008, I entered the office of my hematologist at the HMR. This is where I learned that I had multiple myeloma (I had never heard those words before), and as I was diagnosed at 80%, I was immediately placed under the care of the medical team. From that point on, I felt listened to, supported, encouraged and reassured by the entire staff of the department of hematology and oncology. I decided to trust them and soon realized that I was surrounded by vigilant, competent and passionate people. I’ve had the opportunity to attend lectures and I’ve obtained a lot of documentation over the course of my journey. I know that a website, set up by the research Chair, could be beneficial for patients, physicians and specialists, because the information would be coming from competent sources and could improve the quality of life of many patients. I’ve had chemotherapy, an autologous transplant and a mini allogeneic transplant of stem cells, along with many side effects. I’ve had to practice patience. I am currently in remission and am very grateful to all those who have helped me and help me still. My family, my friends and all the HMR staff have my utmost gratitude.

    Diane Prévost, patient ,